Is Capricor cap1002 a competitor to Avicursen re Dmd, page-6

Also, while CAP is much further along in conversations with the FDA than PER is, PER has had many more interactions with the EMA. As far as I know, CAP is really only starting their conversations with the EMA now. So even if our Phase IIB results underwhelm, we have a significant head start with the EMA. While much of PER's recent commentary has focused on the FDA, hopefully our company hasn't forgotten about the EMA and has kept our relationships there warm. Because depending on how good our and CAP's results are, we may have to view CAP as competition in the anti-inflammatory space.